CAJ | 학술논문

葡萄膜炎、增殖性玻璃体视网膜病变、糖尿病和视网膜静脉阻塞引起的黄斑水肿等难治性眼后节疾病是目前眼科临床亟待解决的重大难题.由于全身给药不良反应大,滴眼液给药疗效差,眼后节植入给药应运而生.近些年,美国食品和药物管理局陆续批准更昔洛韦、醋酸氟轻松和地塞米松3种眼内缓释装置上市并取得了一定的临床疗效,但这些眼内缓释装置的使用仍伴随着手术并发症和药物不良反应的发生.由于巩膜具有表面积大、安全性好、容易给药等优点,随着对载体材料、药物以及给药方式的深入研究,经巩膜给药有望成为治疗眼后节疾病的有效途径.
포도막염、증식성파리체시망막병변、당뇨병화시망막정맥조새인기적황반수종등난치성안후절질병시목전안과림상극대해결적중대난제.유우전신급약불량반응대,적안액급약료효차,안후절식입급약응운이생.근사년,미국식품화약물관리국륙속비준경석락위、작산불경송화지새미송3충안내완석장치상시병취득료일정적림상료효,단저사안내완석장치적사용잉반수착수술병발증화약물불량반응적발생.유우공막구유표면적대、안전성호、용역급약등우점,수착대재체재료、약물이급급약방식적심입연구,경공막급약유망성위치료안후절질병적유효도경.
There is an urgent requirement to find effective therapeutic procedures for the treatment of refractory eye diseases of posterior segment such as posterior uveitis,proliferative vitreoretinopathy,and macular edema associated with diabetes and retinal vein occlusion.Due to systemic side effect developed from systemic drug administration and the low efficiency of topical drug administration,implantable drug devices for the treatment of posterior segment diseases have been explored.In recent years,three different intraocular implantable devices (ganciclovir,fluocinolone acetonide and dexamethasone) have been approved by FDA and showed exciting clinical efficacy.However,these devices have surgical complications and the drug-related side effects.Recently,transscleral drug delivery to the posterior segment has been investigated.Transscleral drug delivery has advantages of large scleral surface area,better safety profile,easily drug administration and could evolve into an effective route with the use of novel biomaterials and the study of drug delivery methods.